The effects of plerixafor on systemic light chain amyloidosis by autologous peripheral blood for stem cell transplantation
Ai Yan
Dong Yan
Yang Hongxia
Fu Weiwei
Abstract：Objective To investigate the effect of plerixafor combined with granulocyte colony stimulating factor(G-CSF)on systemic light chain amyloidosis(AL amyloidosis)by autologous peripheral blood for stem cell transplantation(ASCT).Methods A total of 46 patients diagnosed with AL amyloidosis and undergoing ASCT from July 2021 to July 2023 in General Hospital of Eastern Theater Command,National Clinical Research Center for Kidney Disease were enrolled retrospectively.Among them,23 patients with G-CSF mobilization regimen alone were included in the control group,and 23 patients with plerixafor combined G-CSF mobilization regimen were included in the observation group.The incidence of adverse reactions of stem cell mobilization,stem cell collection and reinfusion,transplantation complications and hematopoietic reconstitution were compared between the two groups.Results The incidence of diarrhoea related to stem cell mobilization in the observation group was higher than that in the control group(P＜0.01).The number of CD34 cells before collection and CD34 cells in the collection in the observation group were higher than those in the control group[(135±97)cells/μl vs(42±21)cells/μl,(6.9±3.5)x 106/kg vs(3.2±1.7)x 106/kg],and the collection cost was lower than that of the control group(all P＜0.01).The amount and cost of stem cell reinfusion in the observation group were lower than those in the control group(both P＜0.01).There was no significant difference in the incidence of complications in the neutropenia period between the two groups(all P＞0.05).The duration of granule deficiency,vertical implantation time,platelet implantation time and length of hospital stay in the observation group were shorter than those in the control group,and the hospitalization cost was lower than that in the control group(all P＜0.05).Conclusions Plerixafor combined with G-CSF mobilization regimen is safe and effective in ASCT for AL amyloidosis.It can reduce the frequency of collection,improve the quality of collection,effectively promote hematopoietic reconstitution,shorten the length of hospital stay,and reduce the cost of hospitalization.
Keywords：Systemic light chain amyloidosisPlerixaforAutologous peripheral blood for stem cell transplantationStem cell mobilization
Publication Date：2024-06-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 872-875 )